E., Ostertag, A., Haguenauer, D
Commonly available GLP-1 RAs include exenatide, liraglutide, dulaglutide, and semaglutide (injectable and oral) 7
Further research is necessary to address the limitations of this study and assess outcomes with semaglutide 2.4 mg treatment beyond 24 months in order to better understand the real-world, long-term effectiveness of semaglutide 2.4 mg for weight management
PlexusDx works with you to define realistic milestones: initial response (48 weeks), significant loss (1216 weeks), and plateau assessment (20+ weeks)
His background in high-acuity care, combined with advanced training in injections and dermatology, ensures precision, safety, and thoughtful patient management throughout your weight loss journey